Ibyra 150 mg Tablet Supplier USA | Pharmaceutical Exporter from India

Ibyra 150 mg Tablet: Advanced PARP Inhibition for Targeted Cancer Therapy

Are you seeking a reliable Ibyra 150 mg tablet exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a leading global supplier and bulk distributor of innovative oncology treatments. We specialize in providing a high-authority, cold-chain-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving precision medicines reach oncology centers with maximum integrity and efficient global logistics.

Detailed Product Overview: What is Ibyra 150 mg?

Ibyra 150 mg Tablet contains the active pharmaceutical ingredient Olaparib. It is a first-in-class, potent PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor. Ibyra represents a breakthrough in precision oncology, specifically designed to target cancer cells with defective DNA repair mechanisms.

Manufactured by Zydus Lifesciences, Ibyra is a high-quality, cost-effective version of the brand Lynparza. For international B2B procurement, Ibyra 150 mg provides a clinically proven maintenance therapy that significantly extends progression-free survival in patients with specific genetic mutations.

Primary Therapeutic Indications

Ibyra 150 mg is clinically indicated for several critical cancer types, particularly those involving BRCA1/BRCA2 mutations:

1. Ovarian Cancer: As maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.

2. Breast Cancer: For the treatment of adult patients with gBRCAm, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy.

3. Pancreatic Cancer: As maintenance treatment for adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma.

4. Prostate Cancer: For adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Mechanism of Action: How Ibyra Works

Ibyra exploits a biological vulnerability in cancer cells known as "synthetic lethality":

• Blocking DNA Repair: PARP is an enzyme that helps repair single-strand breaks in DNA. Ibyra binds to and inhibits the PARP enzyme.

• Trapping PARP: The drug "traps" the PARP enzyme at the site of DNA damage, which leads to the formation of double-strand breaks during DNA replication.

• Targeting BRCA Mutations: In normal cells, these breaks are repaired via homologous recombination. However, in cancer cells with BRCA mutations, this repair pathway is non-functional.

• Cell Death: The accumulation of irreparable DNA damage leads to the death of the cancer cells, while sparing most healthy cells that have intact repair mechanisms.

Administration and Safety Guidelines

• Dosage: The standard recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily, for a total daily dose of 600 mg.

• Usage: Tablets should be swallowed whole; do not chew, crush, or split. It can be taken with or without food.

• Key Precautions:

• Hematological Monitoring: Regular blood counts (CBC) are required to monitor for anemia, neutropenia, and thrombocytopenia.

• MDS/AML Risk: Patients should be monitored for signs of Myelodysplastic Syndrome or Acute Myeloid Leukemia.

• Pneumonitis: New or worsening respiratory symptoms (shortness of breath, cough) should be reported immediately.

• Avoid Grapefruit: Grapefruit and Seville oranges can interact with the medication and should be avoided.

Why Choose Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine Zydus Lifesciences inventory, ensuring 100% product authenticity and competitive wholesale pricing.

• Global Logistics Authority: Expert handling of sensitive oncology medications with a focus on timely delivery to the USA, UK, Australia, and South Africa.

• Regulatory Proof: We provide all necessary documentation, including GMP compliance and Certificates of Analysis (COA).

• Bulk Supply Stability: We specialize in large-scale procurement for hospital groups, government tenders, and regional medical distributors.